Altimmune

ALT NASDAQ IPO2005

about ALT

Altimmune develops vaccines and immunotherapies targeting infectious diseases such as COVID-19, with a focus on innovative prevention and treatment solutions.

type open high low market
cap
volume
stock $4.08 $4.18 $3.86 $426.76M 5.64M
eps price to
earnings
price to
sales
operating
margin
profit
margin
yield
-$0.21 n/a 70997.91 -417180.00% -380280.00% 0%